Catalent (NYSE:CTLT) Rating Increased to Hold at StockNews.com

StockNews.com upgraded shares of Catalent (NYSE:CTLT) from a sell rating to a hold rating in a research note released on Thursday.

A number of other equities research analysts have also recently commented on the company. Baird R W cut Catalent from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 24th. Robert W. Baird reaffirmed a “neutral” rating and issued a $63.50 price objective on shares of Catalent in a research report on Tuesday, September 24th. Finally, William Blair reissued a “market perform” rating on shares of Catalent in a research report on Tuesday, September 3rd. Eight investment analysts have rated the stock with a hold rating, According to MarketBeat, Catalent has an average rating of “Hold” and a consensus target price of $63.40.

Catalent Trading Up 0.3 %

NYSE:CTLT opened at $59.10 on Thursday. Catalent has a 52 week low of $36.74 and a 52 week high of $61.20. The firm has a 50-day moving average price of $59.84 and a two-hundred day moving average price of $58.21. The company has a debt-to-equity ratio of 1.38, a quick ratio of 1.96 and a current ratio of 2.51. The firm has a market cap of $10.73 billion, a price-to-earnings ratio of -26.15, a price-to-earnings-growth ratio of 2.35 and a beta of 1.16.

Catalent (NYSE:CTLT) last released its earnings results on Tuesday, November 5th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.05 by ($0.18). The business had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $1.06 billion. Catalent had a negative net margin of 9.28% and a negative return on equity of 0.66%. The business’s revenue was up 4.2% on a year-over-year basis. During the same period in the prior year, the company earned ($0.10) earnings per share. On average, equities analysts expect that Catalent will post 0.84 earnings per share for the current fiscal year.

Insider Activity at Catalent

In other Catalent news, insider David Mcerlane sold 1,994 shares of the firm’s stock in a transaction dated Thursday, September 26th. The stock was sold at an average price of $59.97, for a total value of $119,580.18. Following the completion of the transaction, the insider now owns 36,304 shares in the company, valued at $2,177,150.88. This trade represents a 5.21 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Michelle R. Ryan sold 2,800 shares of the company’s stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $59.70, for a total value of $167,160.00. Following the sale, the director now owns 10,835 shares in the company, valued at approximately $646,849.50. This represents a 20.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 5,114 shares of company stock worth $305,931. 0.31% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. Millennium Management LLC raised its position in shares of Catalent by 129.2% in the second quarter. Millennium Management LLC now owns 4,079,964 shares of the company’s stock worth $229,416,000 after buying an additional 2,299,784 shares in the last quarter. Bank of Montreal Can raised its holdings in shares of Catalent by 181.5% in the 3rd quarter. Bank of Montreal Can now owns 1,813,167 shares of the company’s stock valued at $109,388,000 after acquiring an additional 1,169,044 shares in the last quarter. National Bank of Canada FI boosted its position in shares of Catalent by 300.0% during the 3rd quarter. National Bank of Canada FI now owns 1,460,813 shares of the company’s stock valued at $88,481,000 after acquiring an additional 1,095,578 shares during the last quarter. Magnetar Financial LLC bought a new stake in shares of Catalent during the 1st quarter valued at about $56,429,000. Finally, Healthcare of Ontario Pension Plan Trust Fund grew its holdings in shares of Catalent by 166.5% during the third quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 1,382,424 shares of the company’s stock worth $83,733,000 after purchasing an additional 863,624 shares in the last quarter.

About Catalent

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.